Por: STJ
The Superior Court of Justice (STJ) rejected the request of Sanofi – Synthelabo to extend the term of patent protection for drug Plavix, indicated for the cases of myocardial infarction, stroke and arterial disease. The Third Panel considered that the term of the patent in Brazil is not the same as his foreign correspondent, so that should be counted from the first filing of a protection, not the patent abroad or the last application for deposit in the country of origin.
Click here to read the full story in portuguese